Phaseline

Companies › Ipsen

Ipsen: clinical trials, targets and expected readouts

8 active drug programs in 42 registered trials: 13 Phase 3, 13 Phase 2, 8 Phase 1, 8 Phase 4; Oncology, Neurology, Immunology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Botulinum Toxin Type A
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
SNAP25Phase 3Chronic Migraine; Episodic Migraine; Obstructed Defaecation Syndrome; Rhizarthrosis …Nov 2026
Corabotase (IPN10200)–Phase 3Moderate to Severe Glabellar Lines; Cervical Dystonia; Episodic Migraine; Moderate to Severe Upper Facial Lines …Dec 2026
Elafibranor
Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist
PPARA, PPARDPhase 3Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC); Primary Sclerosing CholangitisDec 2026
IPN01194–Phase 1MelanomaMar 2028
IPN01195–Phase 1Advanced Solid TumorApr 2028
IPN60300–Phase 1Locally Advanced Solid TumorOct 2028
Tovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Low-grade GliomaJul 2030
IPN01203–Phase 1Advanced Solid TumorJul 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06804993Botulinum Toxin Type APhase 4Obstructed Defaecation SyndromeGastroenterologySep 2023
NCT06814288Botulinum Toxin Type APhase 2Keloid ScarsImmunologyFeb 2025
NCT06814535Botulinum Toxin Type APhase 2Patients with Jaw Muscles Myofascial PainOtherMar 2025
NCT04829565Botulinum Toxin Type APhase 4RhizarthrosisOtherMay 2025
NCT04630873Botulinum Toxin Type APhase 1Post Stroke Spastic HemiplegiaNeurologyAug 2025
NCT06583590Botulinum Toxin Type APhase 2Erectile Dysfunction With Diabetes MellitusMetabolic and endocrineAug 2025
NCT03944876Botulinum Toxin Type APhase 3Cluster HeadacheNeurologySep 2025
NCT06734598Botulinum Toxin Type APhase 4TrismusOncologyNov 2025
NCT05990881Botulinum Toxin Type APhase 3Carpometacarpal SprainInfectious diseaseDec 2025
NCT06839118Botulinum Toxin Type APhase 3Posttraumatic HeadachePsychiatryMar 2026
NCT06878482Botulinum Toxin Type APhase 4Chronic Ulcer of Lower ExtremityImmunologyMar 2026
NCT06047444Botulinum Toxin Type APhase 3Chronic MigraineNeurologyNov 2026
NCT06047457Botulinum Toxin Type APhase 3Episodic MigraineNeurologyNov 2026
NCT07082972Botulinum Toxin Type APhase 4Myofascial Pain Syndrome (MPS)OtherDec 2026
NCT07427797Corabotase (IPN10200)Phase 3Moderate to Severe Glabellar LinesOtherDec 2026
NCT07435428Corabotase (IPN10200)Phase 3Moderate to Severe Glabellar LinesOtherDec 2026
NCT07847541Botulinum Toxin Type APhase 2Temporomandibular DisorderOtherDec 2026
NCT06730061ElafibranorPhase 3Primary Biliary CholangitisGastroenterologyDec 2026
NCT06296082Botulinum Toxin Type APhase 2StrokeNeurologyDec 2026
NCT06448676Botulinum Toxin Type APhase 4WrinkleOtherJan 2027
NCT07399860Botulinum Toxin Type APhase 2HemorrhoidsOtherJan 2027
NCT06411028Botulinum Toxin Type APhase 4Dystonic Tremor SyndromeNeurologyJan 2027
NCT07880860Botulinum Toxin Type APhase 2Cleft LipOtherFeb 2027
NCT06937931Corabotase (IPN10200)Phase 2Cervical DystoniaNeurologyMar 2027
NCT03198702Botulinum Toxin Type APhase 3Obstetrical Brachial Plexus PalsyOtherJun 2027
NCT04821089Corabotase (IPN10200)Phase 1Moderate to Severe Upper Facial LinesImmunologyAug 2027
NCT05720065Botulinum Toxin Type APhase 2Temporomandibular DisordersOtherAug 2027
NCT06625060Corabotase (IPN10200)Phase 2Episodic MigraineNeurologyOct 2027
NCT02216838Botulinum Toxin Type APhase 4Facial FlushingOtherDec 2027
NCT06721520Botulinum Toxin Type APhase 2Esophageal Cancer SurgeryGastroenterologyDec 2027
NCT06305247IPN01194Phase 1MelanomaOncologyMar 2028
NCT06833008IPN01195Phase 1Advanced Solid TumorOncologyApr 2028
NCT07779252Corabotase (IPN10200)Phase 3Moderate to Severe Glabellar LinesOtherApr 2028
NCT07894991Botulinum Toxin Type APhase 2Spinal Cord InjuryNeurologyApr 2028
NCT07213817IPN60300Phase 1Locally Advanced Solid TumorOncologyOct 2028
NCT04526665ElafibranorPhase 3Primary Biliary CirrhosisGastroenterologyDec 2028
NCT04752774Corabotase (IPN10200)Phase 1SpasticityNeurologyMar 2029
NCT06016842ElafibranorPhase 3Primary Biliary Cholangitis (PBC)GastroenterologyMay 2029
NCT07441707TovorafenibPhase 1Low-grade GliomaOncologyJul 2030
NCT07387549ElafibranorPhase 3Primary Sclerosing CholangitisGastroenterologyApr 2031
NCT05627362ElafibranorPhase 2Primary Sclerosing CholangitisGastroenterologySep 2031
NCT07213830IPN01203Phase 1Advanced Solid TumorOncologyJul 2032

Targets

PPARA (1) PPARD (1) SNAP25 (1) RAF1 (1) BRAF (1) ARAF (1)

Companies with the same targets

Roche RDC Clinical Day One Biopharmaceuticals Novartis Hanmi Pharmaceutical Company Pfizer Inventiva Pharma AbbVie Erasca Pierre Fabre Medicament

Companies built like this

Day One Biopharmaceuticals Suzhou Zelgen Biopharmaceuticals Pierre Fabre Medicament Hansoh BioMedical R&D Company Philogen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.